Registration Opens

Breakfast Available

Opening from STAT

Welcome Remarks

Patient Interstitial: Chronically Catherine

Entrepreneurs In Action

These CEOs sold their companies for billions of dollars. Hear the stories behind the deals, and what’s next for these overachievers and the biotech sector as a whole.

The Story of the GLP-1 Obesity Drugs

The new medicines for diabetes and obesity are now the biggest thing in medicine. It wasn’t always so. Come hear the 30-year story of one of the first such treatments.

Eureka Moment: Quantitative Drug Development

New analytics can change the way drug development is done and breaking down silos across teams allows for critical decisions to inform drug development. Hear how we can efficiently and safely get medicines to patients in need through timely pharmacologic modeling and interconnected data science.

How Lilly Delivered and What’s Next

Eli Lilly is now the world’s first half-trillion-dollar biotech company, in part because of this speaker’s R&D decisions. Find out what’s next for new treatments, including those for Alzheimer’s and obesity.

COFFEE BREAK

Biotech’s New Brahmin

Since leaving Alnylam Pharmaceuticals, where he took a technology from Nobel Prize to marketed drug, John Maraganore has been indefatigable, with his hands in one company after another. He’s everywhere – so he’ll probably talk about everything in drug development.

Advancing the Next Wave of Cancer Breakthroughs

Yes, cell therapies have transformed the cancer treatment landscape, but it’s only the beginning. A pioneer in a new type of cell therapy, based on ‘natural killer’ cells, discusses the future of the field, what it takes to advance a risky idea, and the importance of early-career scientists in groundbreaking research.

Introducing the 2023 STAT Wunderkinds

Hear from the next generation of scientific superstars and this year’s class of STAT Wunderkinds. They’ll discuss their groundbreaking work on renal disease, the genetics of psychiatric disorders, and the effects of financial toxicity on health.

LUNCH

Breakout Session | New Analysis: How Medicare Reforms Change Patient Behavior

Be the first to hear a new analysis exploring how historic Medicare Part D reforms could change adherence to treatment. Also, learn why many people on Medicare Part D will continue to turn to charitable patient assistance foundations for support.

Breakout Session | CEO Deep – Dive: Now and Next in our Industry

A visit with three of the most interesting people in biotech. We’ll talk about finding solutions for medical needs, bringing the dream of making drug development patient-centered, and looking ahead to what could happen in biopharma over the next few years.

Transition From Breakout Sessions

A Poet Faces a Chronic Disease

Meghan O’Rourke has long been recognized as one of the most talented stylists of her generation. Her most recent book grapples with her experience of an autoimmune disease, and has thoughtful perceptions on how medicine should change.

A Turning Point for High-Quality Diagnostics in Cancer

Increasingly, physicians are using genomic tests to match the right patient to the right treatment at the right time. But precision cancer care can only be as good as the tests used to guide diagnosis and treatment. As our understanding of cancer improves, new regulatory reforms could make it harder to fulfill the promise of precision cancer by disincentivizing high-quality genomic testing.

Patient Interstitial: A Brain Computer Interface

Funding the Next Generation of Breakthroughs

The Chan Zuckerberg Initiative has a bold goal: to help scientists cure, prevent, or manage all disease. Hear why the organization’s billionaire founders and namesakes believe this seemingly impossible goal is achievable and what they have accomplished so far.

Fireside Chat

Rethinking the Way America Treats Addiction

Methadone is the most effective drug available to treat opioid use disorder, but U.S. law makes it nearly impossible to access. With overdoses at an all-time high, some experts say it is time to radically deregulate medication-assisted treatment.

COFFEE BREAK

Fighting the Hospital System’s Opaque Pricing Practices

Why is it that in medicine, patients cannot find out what something will cost? Hear how one philanthropist is fighting the impenetrable thicket of health care pricing with celebrities as her weapon.

Unlocking the Fourth Great Wave in Cancer Treatment

CAR-Ts are changing the treatment of cancer. But struggles to meet patient demand strain the system, a problem that will worsen as more patients become eligible. What’s needed? An “off-the-shelf” CAR T product that can unlock the promise and democratize access to this powerful fourth wave of cancer treatment.

Dana-Farber’s Big Plan

The news that the iconic cancer center would end its longtime relationship with Brigham and Women’s Hospital to create a new hospital with Beth Israel Deaconess surprised the medical world. Dana-Farber’s CEO argues it is better for patients and for Boston.

Demo: Doctor vs. ChatGPT

We’ll give both an infectious disease expert and an AI interface information about a patient case. Who will make the right diagnosis, the bot or the doc?

Closing Remarks

Closing From STAT

Networking Reception

Afterparty: Celebrating STAT Wunderkinds

Registration Opens

Breakfast Available

Opening from STAT

The Readout LOUD, Live!

Your favorite guides to all things biotech — live in person! Delve into the latest news in this special edition of the weekly podcast series.

Patient Interstitial: Environmental Racism

What Will it Take to End the Crisis of Black Deaths?

In the last two decades, Black Americans have suffered 1.63 million excess deaths and lost more than 80 million years of life compared to white Americans. How do we fix this?

Where East Meets West: The Next Frontier of Integrative Oncology

Patient demand for integrative therapies is on the rise. Yet, despite thousands of years of use and experience with Eastern treatments, few health care organizations provide access to them. City of Hope shares how integrative oncology can be interwoven into the standard of care, improving outcomes and quality of life for cancer patients and survivors.

GSK’s New Groove

After years of waiting, the British drug giant has shed its consumer division and renewed its focus with the launch of a new vaccine for RSV, an infection that causes serious illness in older people. Hear about what’s ahead.

Beyond Buzzwords: Health Equity and Inclusive Research in Action

Since launching the first ever clinical trial focused exclusively on understanding how multiple sclerosis impacts Black and Hispanic/Latinx people, Genentech has continued to listen, learn, act, and partner to make research more representative and healthcare more equitable in MS and other serious diseases. Hear about this journey.

Facing the Firearm Injury Crisis

When Abdullah Pratt was finishing his first year of medical school, his older brother, Rashad, was shot and killed. Now, he fights to preserve other lives, as an emergency medicine physician and by training thousands in health emergency response skills.

COFFEE BREAK

Patient Interstitial: Coverage Denied

Fixing the Health Care System

A simple, tough message: the U.S. healthcare system can’t be renovated. This is a tear-down. Here’s what universal basic health care coverage could look like and how it might work.

We Can End the HIV Epidemic – Why Haven’t We?

The HIV epidemic is now 40 years old. Science and innovation have given us many of the tools to end it, so why is HIV still a thing? Hear about the five things we could do now to end the epidemic.

How New is the New Biogen?

Biogen faced a bruising failure in Alzheimer’s drug development. But now a veteran CEO is aiming to remake the company, powered by a share of an Alzhimer’s drug that is on the market and a new strategy. Hear his plan.

How New is the New Biogen?

LUNCH

A Conversation with Michael J. Fox

He’s a bestselling author, an optimist, and, of course, an icon. Here’s how Michael J. Fox has used his fame to accelerate research and drug development in Parkinson’s disease. Hear the latest about his “business that’s aiming to go out of business,” including a new biomarker that may pave the way for future advances.

Driving Breakthroughs at Boehringer Ingelheim

Patients have counted on Boehringer Ingelheim for breakthroughs for over 138 years, resulting in diverse treatments for cardio-renal-metabolic diseases, oncology, immunology, rare diseases, respiratory illnesses and mental health. Hear more about the magic in this independent company’s unique approach to innovation.

Building Biology’s Century

Flagship Pioneering has been one of the most important company creators of the biotech revolution, with big failures and even bigger successes. Hear how the machine works from the man who built it.

A Call to Action on Maternal Mental Health

The public is increasingly aware of the mental health challenges that can accompany pregnancy and childbirth. New treatments could elevate the standard of care, and public policies can increase their impact. Critical challenges remain. Here’s why we must act with urgency to create a better future for maternal mental health.

COFFEE BREAK

Patient Interstitial: When Cystic Fibrosis Drugs Don’t Work

Protecting Our Health From Climate Change

Over the coming decades warming climates will present a growing problem for health care. We’ll look at how the health care industry can prepare, and at its role in cutting greenhouse emissions.

Patient Interstitial: One Person’s GLP-1 Experience

What’s Next for Obesity Drugs?

What does the future of a world with obesity drugs look like? GLP-1s are changing the landscape of obesity medicine. What do these treatments mean for the drug market and for combating the environmental drivers of obesity?

Closing Remarks

Closing From STAT

Closing Reception

Open to all STAT Summit attendees!